핵의학 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics, Therapeutics), By Application (Cardiology, Neurology, Oncology), By End Use (Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

핵의학 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 핵의학 시장 규모는 2025-2030년 10.16%의 연평균 복합 성장률(CAGR)을 보이고, 2030년까지 345억 1,000만 달러에 달할 것으로 예측됩니다.

암, 갑상선 등 만성질환의 유병률 증가는 시장 성장을 가속할 것으로 예측됩니다. 예측 기간 중 여러 방사성 의약품 치료제가 승인될 것으로 예상되는 것은 시장 성장의 주요 촉진요인이 될 것으로 보입니다. 예를 들어 2022년 3월 노바티스(Novartis AG)는 전립선암 성인 환자 치료제로 플루빅토(Lu 177)를 승인받았습니다.

범미보건기구(PAHO)에 따르면 2022년에는 전 세계에서 약 2,000만 명이 새로 암 진단을 받고 약 1,000만 명이 암으로 사망할 것으로 추정됩니다. 생활습관의 변화, 건강에 해로운 식습관, 중저소득 국가에서 구강 위생에 대한 낮은 인식이 암 유병률의 가장 흔한 원인으로 꼽힙니다.

진단 분야에서 핵의학 제품의 채택이 증가하고 방사성 핵종 공급을 늘리는 데 도움이되는 새로운 발전기의 승인은 성장을 가속할 것으로 예측됩니다. 예를 들어 2021년 11월 EZAG는 브라질에서 GalliaPharm의 브라질 보건 당국 규제기관(ANVISA)의 승인을 받았습니다. 이는 G68 도타테이트 주사제를 만들기 위해 붕괴하는 게르마늄-68공급원에서 양전자를 방출하는 갈륨 동위 원소를 추출하는 데 사용되는 갈륨-68 생성기입니다. 브라질에서 의약품으로 승인된 최초이자 유일한 갈륨 발생기입니다. 이러한 제품의 승인은 신흥 시장에서 시장 개발에 기여할 것입니다.

COVID-19 팬데믹으로 인해 시장은 중간 정도의 영향을 받았으며, 2020년 2분기 국제원자력기구(IAEA)는 원자로 기반 의료용 동위원소에 대한 조사를 실시하여 COVID-19 위기시 공급망 연속성을 평가했습니다. 그 결과, 주요 생산업체들이 IAEA의 안전 기준에 따라 생산을 계속하고 있는 것으로 나타났습니다.

핵의학 시장 보고서 하이라이트

• 제품 유형별로는 SPECT 분야가 저비용, 높은 정확도, 다양한 용도의 폭넓은 사용으로 진단 시장에서 가장 큰 점유율을 차지하고 있습니다.
• PET 분야는 전립선암용 PYLARIFY PET 영상 진단제 등 신제품 승인 및 출시로 예측기간 중 큰 폭의 성장이 예상됩니다.
• 용도별로는 종양 분야가 2024년 시장을 독점합니다.
• 북미는 2024년 42.87%의 점유율로 시장을 독점했으며, 이는 현재 치료법에 대한 인식 개선, 유리한 상환 정책, 환자들의 구매 편의성 향상에 기인합니다.
• 아시아태평양은 만성질환 유병률 증가, 노인 인구 증가, 예측 기간 중 신제품 승인으로 인해 향후 가장 빠르게 성장할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 핵의학 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 핵의학 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 핵의학 시장 : 제품별 추정·동향 분석

• 세계의 핵의학 시장 : 제품별 대시보드
• 세계의 핵의학 시장 : 제품별 변동 분석
• 제품별 매출
• 진단
  • SPECT
  • PET
• 치료법
  • 알파 방사체
  • 베타선 방사체
  • 근접 방사선 요법

제5장 핵의학 시장 : 용도별 추정·동향 분석

• 세계의 핵의학 시장 : 용도별 대시보드
• 세계의 핵의학 시장 : 용도별 변동 분석
• 용도별 매출
• 심장병학
  • SPECT
  • PET
  • 치료에 대한 응용
• 신경학
• 종양학
• 갑상선
  • SPECT
  • 치료에 대한 응용
• 림프종
• 골전이
  • SPECT
  • 치료에 대한 응용
• 내분비 종양
• 폐스캔
• 비뇨기과
• 기타

제6장 핵의학 시장 : 최종 용도별 추정·동향 분석

• 세계의 핵의학 시장 : 최종 용도별 대시보드
• 세계의 핵의학 시장 : 최종 용도별 변동 분석
• 최종 용도별 매출
• 병원
• 진단 센터
• 기타

제7장 핵의학 시장 : 지역별 추정·동향 분석

• 지역별 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2024
  • GE Healthcare.
  • Jubilant Life Sciences Ltd
  • Nordion(Canada), Inc.
  • Bracco Imaging SPA
  • The Institute for Radioelements(IRE)
  • NTP Radioisotopes SOC Ltd.
  • The Australian Nuclear Science and Technology Organization
  • EczacIbasI-Monrol
  • Lantheus Medical Imaging, Inc.
  • Eckert &Ziegler.
  • Mallinckrodt.
  • Cardinal Health.

KSA

영문 목차

영문목차

Nuclear Medicine Market Growth & Trends:

The global nuclear medicine market size is expected to reach USD 34.51 billion by 2030, registering a CAGR of 10.16% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency's (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

Nuclear Medicine Market Report Highlights:

• By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
• The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
• By application, the oncology segment dominated the market in 2024.
• North America dominated the market with a share of 42.87% in 2024, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
• The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Nuclear Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
    • 3.2.1.2. Increasing application of radiopharmaceuticals/nuclear medicine
    • 3.2.1.3. Growing demand for accurate diagnostic methods
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Stringent regulations pertaining to production, storage, & usage
• 3.3. Nuclear Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Nuclear Medicine Market: Product Estimates & Trend Analysis

• 4.1. Global Nuclear Medicine Market: Product Dashboard
• 4.2. Global Nuclear Medicine Market: Product Movement Analysis
• 4.3. Global Nuclear Medicine Market By Product, Revenue
• 4.4. Diagnostics
  • 4.4.1. Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. SPECT
    • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. TC-99m
      • 4.4.2.2.1. TC-99m market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. TL-201
      • 4.4.2.3.1. TL-201 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. GA-67
      • 4.4.2.4.1. GA-67 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.5. I-123
      • 4.4.2.5.1. I-123 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.6. Others
      • 4.4.2.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. PET
    • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.2. F18
      • 4.4.3.2.1. F18 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.3. SR-82/RB-82
      • 4.4.3.3.1. SR-82/RB-82 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.4. PYLARIFY (piflufolastat F 18)
      • 4.4.3.4.1. PYLARIFY (piflufolastat F 18) markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.5. Illuccix (gallium Ga 68 gozetotide)
      • 4.4.3.5.1. Illuccix (gallium Ga 68 gozetotide)s market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3.6. Others
      • 4.4.3.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Therapeutics
  • 4.5.1. Therapeutics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Alpha Emitters
    • 4.5.2.1. Alpha emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.2. RA-223
      • 4.5.2.2.1. RA-223 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2.3. Others
      • 4.5.2.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Beta Emitters
    • 4.5.3.1. Beta emitters market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.2. I-131
      • 4.5.3.2.1. I-131 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.3. Y-90
      • 4.5.3.3.1. Y-90 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.4. SM-153
      • 4.5.3.4.1. SM-153 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.5. Re-186
      • 4.5.3.5.1. Re-186 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.6. Lu-177
      • 4.5.3.6.1. Lu-177 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3.7. Others
      • 4.5.3.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Brachytherapy
    • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.2. Cesium-131
      • 4.5.4.2.1. Cesium-131 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.3. Iodine-125
      • 4.5.4.3.1. Iodine-125 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.4. Palladium-103
      • 4.5.4.4.1. Palladium-103 markets estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.5. Iridium-192
      • 4.5.4.5.1. Iridium-192 market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4.6. Others
      • 4.5.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nuclear Medicine Market: Application Estimates & Trend Analysis

• 5.1. Global Nuclear Medicine Market: Application Dashboard
• 5.2. Global Nuclear Medicine Market: Application Movement Analysis
• 5.3. Global Nuclear Medicine Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 5.4. Cardiology
  • 5.4.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. SPECT
    • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. PET
    • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Therapeutic Applications
    • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Neurology
  • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Thyroid
  • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. SPECT
    • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Therapeutic Applications
    • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Lymphoma
  • 5.8.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Bone Metastasis
  • 5.9.1. Bone metastasis market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. SPECT
    • 5.9.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. Therapeutic Applications
    • 5.9.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Endocrine Tumor
  • 5.10.1. Endocrine tumor market estimates and forecasts 2018 to 2030 (USD Million)
• 5.11. Pulmonary Scans
  • 5.11.1. Pulmonary scans market estimates and forecasts 2018 to 2030 (USD Million)
• 5.12. Urology
  • 5.12.1. Urology market estimates and forecasts 2018 to 2030 (USD Million)
• 5.13. Others
  • 5.13.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Nuclear Medicine Market: End Use Estimates & Trend Analysis

• 6.1. Global Nuclear Medicine Market: End Use Dashboard
• 6.2. Global Nuclear Medicine Market: End Use Movement Analysis
• 6.3. Global Nuclear Medicine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Diagnostic Centers
  • 6.5.1. Diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nuclear Medicine Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. GE Healthcare.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Jubilant Life Sciences Ltd
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Nordion (Canada), Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bracco Imaging S.P.A
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. The Institute for Radioelements (IRE)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. NTP Radioisotopes SOC Ltd.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. The Australian Nuclear Science and Technology Organization
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. EczacIbasI-Monrol
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Lantheus Medical Imaging, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Eckert & Ziegler.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Mallinckrodt.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
  • 8.3.15. Cardinal Health.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives

관련자료